Pembrolizumab combined with nab-paclitaxel and platinum in recurrent/metastatic HNSCC: efficacy, safety, and survival predictive model.

ESMO Open · 2026 · PMC13213764 · PMID 42155319

Europe PMC DOI

hedged sentence

0.0488

closest p · 1.0× alpha

0.0488

boldest claim

The sentences

showed a trendP = 0.0488actually significant

In the HPV-evaluable subset ( n = 132), HPV-negative oropharyngeal squamous cell carcinoma (SCC) showed a trend toward worse median OS compared with non-oropharyngeal SCC (14.8 versus 30.0 months, P = 0.0488).

also in 33,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.